Workflow
Medtronic(MDT)
icon
Search documents
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Prnewswire· 2025-03-30 15:00
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical ...
Prediction: Buying Medtronic Today Will Set You Up for Life
The Motley Fool· 2025-03-28 13:15
Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT -0.21%), one of the largest and most diversified medical device makers.Here's why this is the one healthcare stock I own and why I think it will help set me up for life -- and may do the same for you too if you buy it ...
2 Recession-Proof Dividend Stocks to Buy and Hold
The Motley Fool· 2025-03-27 09:25
Core Viewpoint - Concerns about a potential recession are rising, and investors are advised to consider companies with strong fundamentals that can sustain dividends during economic downturns [1][2] Group 1: Companies with Strong Dividend Records - Companies like Medtronic and Johnson & Johnson are highlighted as strong candidates due to their long history of paying and increasing dividends, indicating robust fundamentals [2][11] - Medtronic has a record of 47 consecutive years of dividend increases, while Johnson & Johnson boasts 62 straight years, showcasing their resilience through various economic cycles [11] Group 2: Resilience During Economic Downturns - During recessions, consumer demand typically decreases, but defensive sectors like healthcare tend to perform better, as medical products and services are often essential [3][6] - Medtronic and Johnson & Johnson provide critical healthcare products that consumers are less likely to forgo, even in tough economic times [4][5] Group 3: Long-Term Growth Prospects - Both companies are positioned for long-term growth due to their leadership in the healthcare industry, which is expected to expand as the global population ages [7] - Medtronic's investments in robotic-assisted surgery and diabetes care, along with Johnson & Johnson's development of new medicines, are anticipated to drive future growth [8][9] Group 4: Market Position and Product Offerings - Medtronic's portfolio includes diabetes care, cardiovascular health, and other critical medical devices, while Johnson & Johnson has a diverse range of drugs and a strong medtech segment [4][5] - The introduction of innovative products, such as Medtronic's Hugo system and Johnson & Johnson's Ottava system for robotic surgery, represents significant growth opportunities [8]
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?
ZACKS· 2025-03-25 17:35
The broader market rally, which pushed the benchmark to a two-week record high yesterday, fueled by tech giants like NVIDIA and Tesla, has provided a much-needed breather for investors. This has potentially set the stage for stocks like Medtronic (MDT) to gain momentum.Over the past couple of months, Medtronic’s stock performance has remained sluggish, declining by 0.8%, reflecting the broader industry trend amid challenges such as aggressive tariff policies, trade tensions, and inflationary pressures. Duri ...
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic
ZACKS· 2025-03-25 08:11
Core Insights - Boston Scientific is currently viewed as a buy due to growth factors despite a recent cooling-off period after a strong 2024 performance where the stock rose by 54.5% [2][21] - The Federal Reserve's cautious stance on interest rates and economic conditions has contributed to market uncertainty, with a warning of a potential stagflationary environment [3][6] - Global trade tensions pose significant risks for Boston Scientific, particularly due to its substantial operations in China and Europe [4][9] Financial Performance - Boston Scientific's stock has outperformed the Zacks Medical Products industry's 4.4% decline and the S&P 500's 4.8% dip in March [5] - The company expects organic revenue growth of 14% to 16% in Q1 2025 and 10% to 12% for the full year, with projected adjusted EPS between $2.80 and $2.87, indicating a growth of 12% to 14% over 2024 [15][16] - The trailing 12-month return on equity for Boston Scientific is 17.8%, surpassing the industry average of 17.3% [19] Market Position and Strategy - Boston Scientific is gaining market share in its MedSurg segment, particularly in endoluminal surgery and single-use imaging franchises [11] - The company is expanding its market share globally in Urology, with strong growth in its Stone management and prosthetic urology franchises [13] - Strategic initiatives include a $150 million investment to expand operations in China and establishing a manufacturing site in Shanghai [8][9] Outlook and Estimates - Analysts have increased the Zacks Consensus Estimate for 2025 EPS following 11 upward estimate revisions, indicating a 2.9% growth from the previous year [18] - The average target price for Boston Scientific is $118.57, reflecting a potential upside of 17.8% from its last closing price of $100.69 [20][23] - Despite macroeconomic headwinds, the company remains confident in sustaining differentiated financial performance throughout 2025 [16][22]
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
ZACKS· 2025-03-24 13:45
Core Insights - The medical sector is increasingly adopting artificial intelligence (AI) for drug synthesis, precise measurement, and faster diagnosis [1] - AI applications in healthcare are enhancing diagnostics, treatment, and operational efficiency, with a projected market value of $95.65 billion by 2025 [4] AI Applications in Healthcare - Generative AI and surgical robotics are being utilized in diagnostic settings to detect image abnormalities that may be missed by human eyes [2] - AI is also improving electronic health records, predictive analytics, and real-time alerting systems [2] Focus on Healthcare Giants - Five healthcare companies are highlighted for their extensive AI applications: Medtronic plc (MDT), Eli Lilly and Co. (LLY), Boston Scientific Corp. (BSX), Novartis AG (NVS), and Abbott Laboratories (ABT) [3][6] Company-Specific Insights Medtronic plc (MDT) - MDT is integrating AI into surgical systems and has developed an AI-powered surgical video management platform [8] - The GI Genius project enhances colorectal cancer detection, increasing survivability by identifying polyps [9] - Expected revenue and earnings growth rates for MDT are 3.4% and 5%, respectively [11] Eli Lilly and Co. (LLY) - LLY focuses on cardiometabolic health, neuroscience, oncology, and immunology, with a strong portfolio in diabetes treatment [12][13] - The company collaborates with OpenAI and invested $409 million in Genetic Leap for AI-driven drug discovery [14] - Expected revenue and earnings growth rates for LLY are 33% and 80.7%, respectively [15] Boston Scientific Corp. (BSX) - BSX is investing in AI-driven health IT solutions to enhance healthcare delivery and clinical outcomes [16] - The company is also focusing on AI-enhanced medical education tools and patient engagement solutions [17] - Expected revenue and earnings growth rates for BSX are 13.8% and 13.6%, respectively [18] Novartis AG (NVS) - NVS is applying AI in generative chemistry, AE brain, and AI nurse applications to innovate patient technologies [19][20] - Expected revenue and earnings growth rates for NVS are 4.1% and 8.5%, respectively [21] Abbott Laboratories (ABT) - ABT utilizes AI for advanced medical imaging and predictive algorithms for heart attack prevention [22] - The company holds a strong position in point-of-care testing across various healthcare areas [23] - Expected revenue and earnings growth rates for ABT are 5.7% and 10.3%, respectively [23]
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?
ZACKS· 2025-03-20 16:35
It has been about a month since the last earnings report for Medtronic (MDT) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Seeking Alpha· 2025-03-20 01:41
Core Insights - The article discusses the investment potential of a specific company, highlighting its strong market position and growth prospects [1][2]. Company Analysis - The company has demonstrated a beneficial long position in its shares, indicating confidence in its future performance [1]. - The analysis emphasizes the company's financial health and strategic initiatives that could drive future growth [1]. Industry Context - The broader industry trends are favorable, with increasing demand for the company's products and services, positioning it well for future expansion [1]. - Competitive landscape analysis suggests that the company is well-positioned against its peers, leveraging its strengths to capture market share [1].
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term
ZACKS· 2025-03-18 14:50
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...
展台直击!36家械企亮点速览 | 2025医学装备大会
思宇MedTech· 2025-03-18 10:14
合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 暂定议程 报名:首届全球心血管大会 | 奖项报名倒计时 报名:首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午,2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家,研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍, 2024年中国医学装备市场规模达到 1.35万亿 元,同比增长 6% 左右 。据了解,目前我国已形成22个大类1100多个 品类的产品体系,是世界上产品类别和品种最齐全的国家之一,产品广泛服务于临床应用,覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中,哪些企业凭借创新亮相引起了行业关注?又有哪些前沿产品和技术成为焦点?思宇将全面回顾展会精彩亮点,供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品, 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ,以及多款前沿技术产品, 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...